Classical pathway complement destruction is not responsible for the loss of human erythrocytes during porcine liver perfusion

Transplantation

Volumn 77, Issue 9 SUPPL., 2004, Pages 1416-1423

  Rees, Michael A ^a,b   Butler, Andrew J ^a   Negus, Margaret C ^a   Davies, Hugh F S ^a   Friend, Peter J ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; ERYTHROCYTE ANTIBODY; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL CIRCULATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT VERSUS HOST REACTION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HEMOLYSIS; LIVER PERFUSION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD55; ANTIGENS, CD59; ANTIGENS, HETEROPHILE; COMPLEMENT PATHWAY, CLASSICAL; ERYTHROCYTES; GRAFT VS HOST DISEASE; HEMOLYSIS; HUMANS; IMMUNOGLOBULIN G; LIVER; PERFUSION; SWINE;

EID: 2442651473     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000121135.24688.A3     Document Type: Article

References (23)

1. Abouna GM. Ex vivo xenogeneic liver perfusion for hepatic failure. Xenotransplantation 1996; 4(6): 102.
2. Fox IJ, Langnas AN, Fristoe LW, et al. Successful application of extracorporeal liver perfusion: A technology whose time has come. Am J Gastroenterol 1993; 88(11): 1876.
3. Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: Properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993; 17(2): 258.
4. Parker W, Saadi S, Lin SS, et al. Transplantation of discordant xenografts: A challenge revisited. Immunol Today 1996; 17(8): 373.
5. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1(9): 964.
6. Butler AJ, Rees MA, Wight DG, et al. Successful extracorporeal porcine liver perfusion for 72 hr. Transplantation 2002; 73(8): 1212.
7. Rees MA, Butler AJ, Chavez-Cartaya G, et al. Prolonged function of extracorporeal hDAF transgenic pig livers perfused with human blood. Transplantation 2002; 73(8): 1194.
8. Rees MA, Butler AJ, Davies HF, et al. Porcine livers perfused with human blood mount a graft-versus-"host" reaction. Transplantation 2002; 73(9): 1460.
9. Harrison RA, Lachmann PJ. Complement Technology. In: Weir DM, Herzenberg LA, Blackwell C, et al., eds. Handbook of experimental immunology. Oxford: Blackwell Scientific Publications 1986, p 39.1.
10. Watkins NJ, Braidley P, Bray CJ, et al. Coating of human decay accelerating factor (hDAF) onto medical devices to improve biocompatibility. Immunopharmacology 1997; 38(1-2): 111.
11. Mushens RE, Scott ML. A fast and efficient method for quantification of monoclonal antibodies in an ELISA using a novel incubation system. J Immunol Methods 1990; 131(1): 83.
12. Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46(6): 825.
13. Johnston PS, Wang MW, Lim SM, et al. Discordant xenograft rejection in an antibody-free model. Transplantation 1992; 54(4): 573.
14. Lachmann PJ. The control of homologous lysis. Immunol Today 1991; 12(9): 312.
15. Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170(3): 637.
16. Hansch GM, Hammer CH, Vanguri P, et al. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 1981; 78(8): 5118.
17. Rollins SA, Zhao J, Ninomiya H, et al. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991; 146(7): 2345.
18. van den Berg CW, Morgan BP. Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J Immunol 1994; 152(8): 4095.
19. Schmoeckel M, Bhatti FN, Zaidi A, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model [published erratum appears in Transplantation 1998 Oct 15;66(7):943]. Transplantation 1998; 65(12): 1570.
20. Schmoeckel M, Bhatti FN, Zaidi A, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model [published erratum appears in Transplantation 1998 Oct 15;66(7):943]. Transplantation 1998; 65(12): 1570.
21. Zaidi A, Schmoeckel M, Bhatti F, et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998; 65(12): 1584.
22. Shichishima T, Saitoh Y, Terasawa T, et al. Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype. Br J Haematol 1999; 104(2): 303.
23. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today 1991; 12(9): 322.